Kinetic and Thermodynamic Characterization of the South African Subtype C HIV-1 Protease: Implications for Drug Resistance

Salerwe Mosebi

A thesis submitted to the Faculty of Science, University of the Witwatersrand, Johannesburg, in fulfilment of the requirement for the degree of Doctor of Philosophy

Johannesburg, July 2007

DECLARATION

I declare that this thesis is my own, unaided work. It is being submitted for the degree of Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has not been submitted for any degree or examination in any other University.

Salerwe Mosebi

this day of 2007

I dedicate this work to the precious people in my life who have unselfishly supported my choice of paths:

My parents: Abuti Thabo and Ausi Tshidi for all the endless support and encouragement over the years

My brother: Semana, you are the best brother in the world

In the memory of my grandparents: Papi and Mma Mosebi

"It is not hard to see that the possibility of scientific advance is closely connected with the role of heterodoxy, since new ideas and discoveries have to emerge initially as heterodox views, which differ from, and may be in conflict with, established understanding. The history of scientific contributions across the world – the experiences of Copernicus, or Galileo, or Newton, or Darwin – shows many examples of the part that resolute heterodoxy has to play, in scrutinizing, and when necessary rejecting, the views that are standardly accepted".

Professor Amartya Sen

ABSTRACT

The magnitude of the AIDS epidemic is well documented. It has been shown that Africa constitutes about 70 % of people infected with HIV worldwide. Efforts to control the AIDS epidemic have focused heavily on studies pertaining to the biology, biochemistry and structural biology of HIV and on the interactions between HIV proteins and new drugs. One of the most challenging problems in AIDS therapy is that HIV develops drug-resistant variants rapidly. Extensive research has been dedicated to designing resistance-evading drugs for HIV-1 protease (predominantly subtype B), which is crucial for the maturation of viral, structural and enzymatic proteins. There are 10 subtypes of HIV-1 within the major group of the virus, with subtype C accounting for about 95 % of infections in South Africa. Since HIV-1 antiretroviral treatment has been developed and tested against the B subtype, which is prevalent in North America, Western Europe and Australia, an important question relates to the effectiveness of these drugs against the C subtype. At this point, however, little is known about inhibitor-resistant mutations in the subtype C. The study, therefore, looked at the two active site mutations (V82A and V82F/I84V) in the South African HIV-1 subtype C protease (C-SA) emerging from the viral population circulating in patients. These mutations are well-characterized within the framework of the subtype B and are known to cause cross-resistance to most of inhibitors currently in clinical use. Protein engineering techniques were used to generate the V82A and the V82F/I84V variants. Comparative studies with the wild-type HIV-1 C-SA protease were performed. The spectral properties of the V82A and the V82F/I84V variants indicated no changes in the secondary structure in the respective variant proteins. Tryptophan and tyrosine fluorescence indicated a major difference in the intensities at the emission maxima for all three proteins. The fluorescence intensity of the V82F/I84V variant, in particular, was significantly enhanced indicating the occurrence of tertiary structural changes at/near the flap region. Both mutations did not impact significantly upon catalytic function. Both variants also had the same K_m values comparable to that of the wild-type enzyme. The catalytic efficiencies and the kinetic constants were lowered 3.6-fold for the V82A mutation and 6-fold for the V82F/I84V mutation relative to the wild-type C-SA protease. Inhibition studies were performed using four inhibitors in clinical use (saquinavir, ritonavir, indinavir and nelfinavir). For the V82A variant, IC_{50} and K_i values for saquinavir and nelfinavir

were not affected, whilst those for ritonavir and indinavir were 5- and 9-fold higher than the wild-type C-SA protease, respectively. Against the V82F/I84V variant, however, the inhibition constants were drastically weaker and characterized by IC_{50} and K_i ratios ranging from 50 to 450. Isothermal titration calorimetry (ITC) was also used to determine the binding energetics of saquinavir, ritonavir, indinavir and nelfinavir to the wild-type C-SA, V82A and V82F/I84V HIV-1 protease. The V82A mutation lowered the Gibbs energy of binding for the respective four clinical inhibitors by 0.4 kcal/mol, 1.3 kcal/mol, 1.5 kcal/mol and 0.6 kcal/mol, respectively, relative to the wild-type C-SA HIV-1 protease. The affinity of V82A HIV-1 protease for saquinavir, ritonavir, indinavir and nelfinavir (K_d = 1.85 nM, 2.00 nM, 12.70 nM and 0.66 nM, respectively, at 25 °C) was in the range of 2- to 13-fold of magnitude weaker than that of the wild-type C-SA protein. The clinical inhibitors exhibited the highest binding affinity to both the wild-type and the V82A enzymes, but were extremely sensitive to the V82F/I84V mutation. The V82F/I84V mutant reduced the binding of saquinavir, ritonavir, indinavir and nelfinavir 117-, 1095-, 474- and 367-fold, respectively. A drop in K_d values obtained for the V82F/I84V in association with saquinavir, ritonavir, indinavir and nelfinavir was consistent with a decrease of between 2.8 - 4.2 kcal/mol in ΔG, which is equivalent to at least 2 to 3 orders of magnitude in binding affinity. Taken together, thermodynamic data indicated that the V82A and V82F/I84V active site mutations in the C-SA subtype lower the affinity of the first-generation inhibitors by making the binding entropy less positive (unfavorable) and making the enthalpy change slightly less favorable.

ACKNOWLEDGEMENTS

My supervisor, Dr. Yasien Sayed, for his continuous assistance, support and motivation. Thank you for always being my pillar of strength.

Professor Heini Dirr for his continuous guidance, encouragement, support and professionalism over the course of my studies. Thank you for giving me the opportunity to be part of a highly enthusiastic team and the privilege of working in your laboratory.

The members of the Protein Structure-Function Research Unit, University of the Witwatersrand.

The CSIR for hosting and training me on the use of the high performance liquid chromatography for purification of the clinical inhibitors.

The University of the Witwatersrand, the Andrew Mellon Foundation and the National Research Foundation of South Africa for financial assistance.

TABLE OF CONTENTS

DECLARATION **ii**

ABSTRACT **iv**

ACKNOWLEDGEMENTS **v**

ABBREVIATIONS **ix**

LIST OF FIGURES **xii**

LIST OF TABLES **xiii**

Chapter 1 **1**

1. Molecular recognition 1

1.1 Lock-and-key versus induced fit mechanism of ligand binding 1

1.2 Protein-protein and protein-ligand interactions 2

1.2.1 Polar interactions 2

1.2.2 Hydrophobic interactions 3

1.3 Protein binding energetics and isothermal titration calorimetry 4

1.4 Thermodynamic leads in drug design 8

1.5 HIV and AIDS 11

1.6 Structure of HIV-1 protease 16

1.7 Catalytic mechanism of the HIV-1 protease 21

1.8 Inhibition and development of drug resistance 25

1.8.1 Saquinavir 32

1.8.2 Ritonavir 32

1.8.3 Indinavir 34

1.8.4 Nelfinavir 35

1.8.5 Amprenavir 35

1.8.6 Lopinavir 35

1.8.7 Atazanavir 36

1.8.8 Tipranavir 36

1.8.9 Darunavir 37

1.9 Polymorphisms and resistance mutations in HIV-1 protease from African subtypes 37

1.10 Objectives 42

Chapter 2 **43**

2. Experimental procedures 43

2.1 Materials 43

2.2 Source of sequence data 43

2.3 Source of HIV-1 protease and expression plasmid 43

2.4 Verification of the wild-type pET-11b plasmid 44

2.5 Protein engineering 44

2.5.1 Oligonucleotide primer design 44

2.5.2 Mutagenesis 44

2.5.3 Sequencing of mutant plasmid DNA 45

2.5.4 Transformation of plasmid DNA into *Escherichia coli* BL21 (DE3) pLysS cells 45

2.6 Over-expression and purification of the HIV-1 protease 46

2.7 Purification of clinical inhibitors 47

2.8 Protein concentration determination 47

2.8.1 HIV-1 protease active site concentration determination 48

2.9 SDS-PAGE 49

2.10 SE-HPLC 49

2.11 Spectroscopic studies of the wild-type, V82A and V82F/I84V HIV-1 protease 49

2.11.1 Circular dichroism 49

2.11.2 Far-UV circular dichroism of the wild-type C-SA, V82A and V82F/I84V HIV-1 proteases 50

2.11.3 Steady-state fluorescence 50

2.12 Determination of kinetic parameters 51

2.13 Inhibition studies 51

2.14 Isothermal titration calorimetry 52

2.14.1 Energetics of saquinavir binding to the wild-type, V82A and V82F/I84V HIV-1 proteases 53

2.14.2 Energetics of ritonavir binding to the wild-type, V82A and V82F/I84V HIV-1 proteases 53

2.14.3 Energetics of indinavir binding to the wild-type, V82A and V82F/I84V HIV-1 proteases 54

2.14.4 Energetics of nelfinavir binding to the wild-type, V82A and V82F/I84V HIV-1 proteases 54
2.15 Protein crystallography 54
2.16 Data analysis and molecular graphics 55

Chapter 3 **56**
3. Results 56
3.1 Verification of the pET-11b plasmid DNA 56
3.2 Over-expression and purification of the wild-type and variant HIV-1 proteases 56
3.3 Spectroscopic properties of the wild-type and variant HIV-1 proteases 60
3.3.1 Far UV-CD 60
3.3.2 Spectral properties of the wild-type C-SA, V82A and V82F/I84V HIV-1 proteases 60
3.4 Characterization of the wild-type C-SA, V82A and V82F/I84V variant proteases 64
3.4.1 Effects of the V82A and V84F/I84V mutations on the catalytic activity of the C-SA protease 64
3.4.2 Enzyme inhibition 64
3.4.3 Energetics of peptide inhibitor binding 71
3.4.4 Energetics of inhibitor binding to wild-type C-SA, V82A and V82F/I84V HIV-1 proteases 76
3.4.5 Viral fitness 93
3.5 Crystallographic studies 95

Chapter 4 **97**
4. Discussion 97
4.1 Spectral properties of the wild-type, V82A and V82F/I84V HIV-1 proteases 97
4.1.1 Far-UV circular dichroism 97
4.1.2 Fluorescence spectral properties 97
4.2 Effects of the V82A and V82F/I84V mutations on substrate binding 100
4.3 Effect of C-SA natural polymorphisms on inhibitor efficiency 102
4.4 Structural implications of the V82A and V82F/I84V mutations on clinical inhibitor binding 103
4.5 Thermodynamics of clinical inhibitor binding 115

4.6 Conclusions 123

REFERENCES **124**

Appendix **153**

ABBREVIATIONS

ABC	abacavir
AIDS	aquired immune deficiency syndrome
ATV	atazanavir
AZT	zidovudine
bp	base pairs
CA	capsid protein
CD	circular dicroism
ΔCp	change in heat capacity
DMSO	dimethyl sulfoxide
DTT	1,4-dithiothreitol
DNA	deoxyribonucleic aicd
ddc	zalcitabine
ddI	didanosine
d4T	stavudine
3TC	lamivudine
DEAE	diethylaminoethyl
DLV	delavirdine
EDTA	ethylenediaminetetra-acetic-acid
EIAV	equine infectious anemia acid
EFV	efavirnez
fAPV	fosamprenavir
FDA	Food and Drug Administration
FTC	entricitabine
FIV	feline immunodeficiency virus
Gag	group specific antigen
ΔG	change in Gibbs free energy
ΔH	change in enthalpy
HIV	human immunodeficiency virus
HAART	highly active anti-retroviral treatment
IN	integrase
IDV	indinavir
IPTG	ß-isopropylthiogalactoside
ITC	isothermal titration calorimetry

K_a	association constant
K_d	dissociation constant
kDa	kilodalton
K_i	inhibition constant
K_m	Michaelis-Menten constant
MA	matrix protein
LPV	lopinavir
NFV	nelfinavir
NC	nucleocapsid protein
NNRTI	non-nucleoside reverse transcriptase inhibitor
NVP	nevirapine
ORF	open reading frame
PDB	protein data bank
PCR	polymerase chain reaction
PMSF	phenylmethylsulfonylfluoride
Pol	polymerase
PR	protease
RNA	ribonucleic acid
RNase	ribonuclease
rpm	revolutions per minute
RSV	Rous sarcoma virus
RT	reverse transcriptase
RTV	ritonavir
ΔS	change in entropy
SDS-PAGE	sodium dodecylsulfate polyacrylamide gel electrophoresis
SE-HPLC	size exclusion high performance liquid chromatography
SIV	simian immunodeficiency virus
SQV	saquinavir
TDF	tenofovir
TFA	trifluoroacetic acid
TF	transmembrane protein
THF	tetrahydrofuranylurethane
TPV	tipranavir
V82A	replacement of wild-type valine (V) with alanine at position 82

V82F/I84V	replacement of wild-type valine (V) with phenylalanine (F) at position 82 and of wild-type isoleucine (I) with valine (V) at position 84
V_m	maximum velocity

The IUPAC-IUBMB one and three letter codes for amino acids are used

LIST OF FIGURES

Figure 1. Life cycle of HIV

Figure 2. Schematic representation of the HIV-1 gag and pol reading frames depicting their polyprotein translation products

Figure 3. Ribbon representation of the structure of the homodimeric HIV-1 subtype B protease in complex with acetyl-pepstatin

Figure 4. Ribbon representations of the ligand-free homodimeric HIV-1 protease and in complex with acetyl-pepstatin in the active site

Figure 5. A schematic diagram showing the conventional nomenclature used to assign amino acid residues of peptide substrates as well as the corresponding binding sites on the protease molecule

Figure 6. Schematic representation of the proposed kinetic mechanism of HIV protease

Figure 7. Chemical structures of saquinavir, ritonavir and indinavir

Figure 8. Chemical structures of nelfinavir, amprenavir and lopinavir

Figure 9. Chemical structures of atazanavir, tipranavir and darunavir

Figure 10. A ribbon representation of HIV-1 protease homodimer with positions of amino acid residues associated with clinical resistance to current protease inhibitors

Figure 11. A ribbon representation of the homodimeric structure of HIV subtype B protease illustrating the polymorphic positions in the South African subtype C protease sequences

Figure 12. A graphical representation showing the polymorphisms in the subtype C protease from drug-naïve South African patients. The sequence alignment for the protease from the HIV-1 B and C subtypes are also shown

Figure 13. 1 % agarose gel separation of pET-11b plasmid DNA restricted with *Bam*HI and *Nde*I

Figure 14. DNA sequencing electrophoretogram of the V82A and V82F/I84V substitutions introduced into pET-11b coding region of the HIV-1 protease

Figure 15. SDS-PAGE analysis of wild-type C-SA, V82A and V82F/I84V HIV-1 protease

Figure 16. SEC-HPLC elution profile for wild-type HIV-1 protease

Figure 17. Far-UV circular dichroism spectra of the wild-type, V82A and the V82F/I84V HIV-1 protease

Figure 18. Trp and Tyr emission spectra of the wild-type, V82A and V82F/I84V HIV-1 protease

Figure 19. Specific activity determination for the wild-type C-SA, V82A and V82F/I84V protease

Figure 20. Michaelis-Menten plot for the determination of K_m for wild-type C-SA HIV-1 protease towards the chromogenic substrate

Figure 21. Michaelis-Menten plot for the determination of K_m for V82A HIV-1 protease towards the chromogenic substrate

Figure 22. Michaelis-Menten plot for the determination of K_m for V82F/I84V HIV-1 protease towards the chromogenic substrate

Figure 23. Representative calorimetric profile for the titration of wild-type HIV-1 protease with acetyl-pepstatin

Figure 24. Representative calorimetric profile for the titration of the V82A HIV-1 protease with acetyl-pepstatin

Figure 25. Representative calorimetric profile for the titration of the V82F/I84V HIV-1 protease with acetyl-pepstatin

Figure 26. Overview of a displacement titration assay for HIV-1 protease

Figure 27. Displacement calorimetric titration of saquinavir into a solution of the wild-type C-SA HIV-1 protease pre-bound to acetyl-pepstatin

Figure 28. Displacement calorimetric titration of ritonavir into a solution of the wild-type C-SA HIV-1 protease pre-bound to acetyl-pepstatin

Figure 29. Displacement calorimetric titration of indinavir into a solution of the wild-type C-SA HIV-1 protease pre-bound to acetyl-pepstatin

Figure 30. Displacement calorimetric titration of nelfinavir into a solution of the wild-type C-SA HIV-1 protease pre-bound to acetyl-pepstatin

Figure 31. Displacement calorimetric titration of saquinavir into a solution of the V82A HIV-1 protease pre-bound to acetyl-pepstatin

Figure 32. Displacement calorimetric titration of ritonavir into a solution of the V82A HIV-1 protease pre-bound to acetyl-pepstatin

Figure 33. Displacement calorimetric titration of indinavir into a solution of the V82A HIV-1 protease pre-bound to acetyl-pepstatin

Figure 34. Displacement calorimetric titration of nelfinavir into a solution of the V82A HIV-1 protease pre-bound to acetyl-pepstatin

Figure 35. Representative calorimetric profile for the direct titration of the V82F/I84V HIV-1 protease with saquinavir

Figure 36. Representative calorimetric profile for the direct titration of ritonavir with the V82F/I84V HIV-1 protease

Figure 37. Representative calorimetric profile for the direct titration of the V82F/I84V HIV-1 protease with indinavir

Figure 38. Representative calorimetric profile for the direct titration of the V82F/I84V HIV-1 protease with nelfinavir

Figure 39. Tetragonal bipyramidal crystals of the wild-type C-SA HIV-1 protease

Figure 40. Ribbon representation of the structure of a ligand-free HIV-1 protease

Figure 41. Hydrogen bond interactions between the wild-type, V82A HIV-1 subtype B protease and saquinavir

Figure 42. Structural superimposition of residues 80-84 in the wild-type and V82A subtype B HIV-1 protease in complex with saquinavir

Figure 43. Backbone alpha-carbon traces for the structural superposition of wild-type and mutant V82A subtype B HIV-1 protease in complex with ritonavir

Figure 44. A ribbon representation of the homodimeric structure of HIV-1 protease indicating the topographical positions occupied by the 8 consensus amino acid residues in the South African C subtype

LIST OF TABLES

Table 1. Primary and secondary resistance mutations in HIV-1 subtype B protease associated with the development of resistance against currently approved protease inhibitors

Table 2. Kinetic parameters for the wild-type, V82A and V82F/I84V HIV-1 protease

Table 3. Comparison of the inhibition characteristics (IC_{50}) of the wild-type C-SA, V82A and V82F/I84V HIV-1 protease

Table 4. Inhibition constants (K_i) for the wild-type C-SA, V82A and V82F/I84V HIV-1 protease

Table 5. Thermodynamic parameters for the binding of acetyl-pepstatin to the HIV-1 proteases: Wild-type C-SA, V82A and V82F/I84V

Table 6. Thermodynamics parameters for the binding of inhibitors to wild-type C-SA, V82A and V82F/I84V HIV-1 protease

Table 7. Table showing vitality values of the V82A and V82F/I84V HIV-1 protease

Table 8. Relative changes for the binding inhibitors to the wild-type C-SA, V82A and V82F/I84V proteases using the wild-type B subtype as a reference